Your basket is currently empty!
Major changes to the current Cancer Drugs Fund
As previously reported, some major changes to the current Cancer Drugs Fund (CDF) are due to be reported this year.
We would like to inform you that the changes have been delayed until July 1, 2016. Part of the CDF changes involve the introduction of a new rapid reconsideration process, where drugs that have previously not been recommended will be reconsidered by NICE. From the drugs used in kidney cancer, the drug everolimus has been put forward for rapid reconsideration. Everolimus was previously appraised and rejected as a second line treatment, so we are presuming that the drug is again being appraised as a second line treatment. At the beginning of the reconsideration process, drug companies are able to alter the pricing of the drug and new evidence is also invited. Potentially this might alter whether the drug is recommended by NICE. The anticipated publication of this document is February 2017.
Included in the table below are the other two NICE appraisals that are occurring in the near future which involve drugs used in kidney cancer. We will keep you updated about any developments in this area. For more information on what is planned and why, please read our previous article on the ‘Cancer Drugs Fund changes and what it could mean to you’ here,
|Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]||Anticipated publication date: TBC|
|Renal cell carcinoma – everolimus (review of TA219) [ID1015] – CDF rapid reconsideration process||Anticipated publication date: February 2017|
|Renal cell carcinoma (metastatic, treated) – nivolumab [ID853]||Anticipated publication date: October 2016|